Pathologic interpretation of endoscopic ultrasound–guided fine needle aspiration cytology/biopsy for pancreatic lesions
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Pathologic interpretation of endoscopic ultrasound–guided fine needle aspiration (EUS-FNA) cytology/biopsy specimens is one of the most challenging tasks in cytology and surgical pathology practice, as the procedure often yields minimal amounts of diagnostic material and contains contaminants, such as blood cells and normal intestinal mucosa. EUS-FNA cytology/biopsy will nevertheless become a more popular procedure for evaluation of various pancreatic lesions because they are difficult to approach with conventional endoscopic procedures. Pathologists should understand the structural differences and limitations of EUS-FNA that make pathologic diagnosis difficult. Ancillary tests are available for differential diagnosis of EUS-FNA for various pancreatic lesions. Immunostains are the most commonly used ancillary tests, and pathologists should able to choose the necessary panel for differential diagnosis. Pathologists should review clinical history and radiologic and/or EUS findings before selecting an immunostain panel and making a pathologic diagnosis. In addition, one’s threshold of malignancy should be adjusted according to the appropriate clinical setting to avoid under-evaluation of pathologic diagnoses. Clinico-pathologic correlation is essential in pathologic evaluation of EUS-FNA for pancreatic lesions. Pathologists can reduce errors by correlating clinical and radiologic findings when evaluating EUS-FNA. Some molecular tests can be applied in differential diagnosis of pancreatic neoplastic and cystic lesions. Molecular data should be used as supportive evidence of a specific disease entity, rather than direct evidence, and should be correlated with clinico-pathologic findings to avoid errors in pathologic diagnosis.
Abstract
Pathologic interpretation of endoscopic ultrasound–guided fine needle aspiration (EUS-FNA) cytology/biopsy specimens is one of the most challenging tasks in cytology and surgical pathology practice, as the procedure often yields minimal amounts of diagnostic material and contains contaminants, such as blood cells and normal intestinal mucosa. EUS-FNA cytology/biopsy will nevertheless become a more popular procedure for evaluation of various pancreatic lesions because they are difficult to approach with conventional endoscopic procedures. Pathologists should understand the structural differences and limitations of EUS-FNA that make pathologic diagnosis difficult. Ancillary tests are available for differential diagnosis of EUS-FNA for various pancreatic lesions. Immunostains are the most commonly used ancillary tests, and pathologists should able to choose the necessary panel for differential diagnosis. Pathologists should review clinical history and radiologic and/or EUS findings before selecting an immunostain panel and making a pathologic diagnosis. In addition, one’s threshold of malignancy should be adjusted according to the appropriate clinical setting to avoid under-evaluation of pathologic diagnoses. Clinico-pathologic correlation is essential in pathologic evaluation of EUS-FNA for pancreatic lesions. Pathologists can reduce errors by correlating clinical and radiologic findings when evaluating EUS-FNA. Some molecular tests can be applied in differential diagnosis of pancreatic neoplastic and cystic lesions. Molecular data should be used as supportive evidence of a specific disease entity, rather than direct evidence, and should be correlated with clinico-pathologic findings to avoid errors in pathologic diagnosis.
참고문헌 (34)
- DiMagno EP, "Ultrasonic endoscope", Lancet, 1, pp.629~631 (1980)
- Vilmann P, "Endoscopic ultrasonography with guided fine needle aspiration biopsy in pancreatic disease", Gastrointest Endosc, 38, pp.172~173 (1992)
- Chun JW, "Comparison of liquid-based cytology with conventional smear cytology for EUS-guided FNA of solid pancreatic masses : a prospective randomized noninferiority study", Gastrointest Endosc, 91, pp.837~846 (2020)
- Mitoro A, "Diagnostic efficacy of liquid-based cytology in endoscopic ultrasound-guided fine needle aspiration for pancreatic mass lesions during the learning curve : a retrospective study", Pancreas, 48, pp.686~689 (2019)
- Yung RC, "Improvement of cellularity on cell block preparations using the so-called tissue coagulum clot method during endobronchial ultrasound-guided transbronchial fine-needle aspiration", Cancer Cytopathol, 120, pp.185~195 (2012)
- Lee KS, "Prevalence of incidental pancreatic cysts in the adult population on MR imaging", Am J Gastroenterol, 105, pp.2079~2084 (2010)
- Wittmann J, "Endoscopic ultrasound-guided tissue sampling by combined fine needle aspiration and trucut needle biopsy : a prospective study", Cytopathology, 17, pp.27~33 (2006)
- Lee YN, "Tissue acquisition for diagnosis of biliary strictures using peroral cholangioscopy or endoscopic ultrasound-guided fine-needle aspiration", Endoscopy, 51, pp.50~59 (2019)
- Lee JK, "A prospective, randomized trial comparing 25-gauge and 22-gauge needles for endoscopic ultrasoundguided fine needle aspiration of pancreatic masses", Scand J Gastroenterol, 48, pp.752~757 (2013)
- Rindi G, "A common classification framework for neuroendocrine neoplasms : an International Agency for Research on Cancer(IARC)and World Health Organization(WHO)expert consensus proposal", Mod Pathol, 31, pp.1770~1786 (2018)
- Misdraji J, "Ancillary tests in the diagnosis of liver and pancreatic neoplasms", Cancer Cytopathol, 126(Suppl 8), pp.672~690 (2018)
- Li J, "How reliable is the Ki-67 cytological index in grading pancreatic neuroendocrine tumors? A meta-analysis", J Dig Dis, 17, pp.95~103 (2016)
- Weynand B, "Pancreatic neuroendocrine tumour grading on endoscopic ultrasound-guided fine needle aspiration : high reproducibility and inter-observer agreement of the Ki-67 labelling index", Cytopathology, 25, pp.389~395 (2014)
- Hwang HS, "Grading by the Ki-67 labeling index of endoscopic ultrasound-guided fine needle aspiration biopsy specimens of pancreatic neuroendocrine tumors can be underestimated", Pancreas, 47, pp.1296~1303 (2018)
- Kim SA, "Pleomorphic solid pseudopapillary neoplasm of the pancreas : degenerative change rather than high-grade malignant potential", Hum Pathol, 45, pp.166~174 (2014)
- Seokhwi Kim, "Isolated Mass-Forming IgG4-Related Cholangitis as an Initial Clinical Presentation of Systemic IgG4-Related Disease", Journal of Pathology and Translational Medicine, 50(4), pp.300~305 (2016), 대한병리학회[DOI]
- Lee HE, "Immunoglobulin G4-related hepatobiliary disease", Semin Diagn Pathol, 36, pp.423~433 (2019)
- Heymann JJ, "Ancillary techniques in cytologic specimens obtained from solid lesions of the pancreas : a review", Acta Cytol, 64, pp.103~123 (2020)
- Layfield LJ, "Utilization of ancillary studies in the cytologic diagnosis of biliary and pancreatic lesions : the Papanicolaou Society of Cytopathology guidelines for pancreatobiliary cytology", Diagn Cytopathol, 42, pp.351~362 (2014)
- Soyer OM, "Role of biochemistry and cytological analysis of cyst fluid for the differential diagnosis of pancreatic cysts : a retrospective cohort study", Medicine (Baltimore), 96, pp.e5513~ (2017)
- Kubiliun N, "EUS-FNA with rescue fluorescence in situ hybridization for the diagnosis of pancreatic carcinoma in patients with inconclusive on-site cytopathology results", Gastrointest Endosc, 74, pp.541~547 (2011)
- Wu J, "Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development", Sci Transl Med, 3, pp.92ra66~ (2011)
- Jones M, "Impact of next-generation sequencing on the clinical diagnosis of pancreatic cysts", Gastrointest Endosc, 83, pp.140~148 (2016)
- Ngamruengphong S, "Analysis of pancreatic cyst fluid", Surg Pathol Clin, 9, pp.677~684 (2016)
- Rosenbaum MW, "Next-generation sequencing adds value to the preoperative diagnosis of pancreatic cysts", Cancer Cytopathol, 125, pp.41~47 (2017)
- Hartley CP, "FNA smears of pancreatic ductal adenocarcinoma are superior to formalin-fixed paraffin-embedded tissue as a source of DNA : Comparison of targeted KRAS amplification and genotyping in matched preresection and postresection samples", Cancer Cytopathol, 125, pp.838~847 (2017)
- Park YJ, "Histopathologic discrepancies between endoscopic forceps biopsy and endoscopic resection specimens in superficial esophageal squamous neoplasms", J Gastroenterol Hepatol, 34, pp.1058~1065 (2019)
- Ilie M, "Comparative study of the PDL1status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances : a potential issue for anti-PD-L1 therapeutic strategies", Ann Oncol, 27, pp.147~153 (2016)
- Cros J, "Tumor heterogeneity in pancreatic adenocarcinoma", Pathobiology, 85, pp.64~71 (2018)
- Prasetyanti PR, "Intra-tumor heterogeneity from a cancer stem cell perspective", Mol Cancer, 16, pp.41~ (2017)
- Allenson K, "High prevalence of mutant KRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients", Ann Oncol, 28, pp.741~747 (2017)
- Takai E, "Clinical utility of circulating tumor DNA for molecular assessment and precision medicine in pancreatic cancer", Adv Exp Med Biol, 924, pp.13~17 (2016)
- Torres C, "Pancreatic cancer subtypes : a roadmap for precision medicine", Ann Med, 50, pp.277~287 (2018)
- Chantrill LA, "Precision medicine for advanced pancreas cancer : the Individualized Molecular Pancreatic Cancer Therapy(IMPaCT)trial", Clin Cancer Res, 21, pp.2029~2037 (2015)